Kintiga™ to be officially launched at the World EPA Congress in Amsterdam, 5-6 March 2025
- Under the new shared name, gold sponsors, Kintiga, formerly MAP Patient Access, AxTalis, and SKC, invite you to meet their market access specialists from across Europe.
- Professor Matthias Schönermark, Kintiga’s Chief Corporate Development Officer, will chair a session on the strategic perspective on EU HTA
Cambridge, UK, 26 February 2025 – Kintiga, formerly known as The MAP Group, a pan-European specialist pharmaceutical and biotechnology strategic consultancy focused on driving therapies through the complex medical, regulatory and market access landscape to maximise success in Europe, today announced their activities at the upcoming World Evidence, Pricing and Access (EPA) Congress in Amsterdam on 5-6 March 2025. The World EPA Congress is Europe’s largest event focused on market access, pricing, and evidence, bringing together over 1,500 industry leaders, policymakers, and experts. With 300 speakers and eight dedicated tracks, the congress serves as a key forum for discussions on the current and future state of market access in Europe.
As a gold Sponsor of World EPA, Kintiga will host and be involved in several events at the Congress:
Kintiga team at exhibit booth #40
- Please join our team of experts to discuss navigating the complex path to patient access in Europe with confidence and learn more about Kintiga
- Enjoy a latte or cappuccino on us, as we will have a barista on the booth throughout the conference
- Enter to win a ‘War Gaming Workshop” to test and refine your market access strategic decision-making with experts in the field of EU HTA
- Pick up your copy of the newest edition of the White Paper: ‘One HTA Regulation for All – harmonisation & simplification’
Kintiga reception
- Take a break and optimise your networking time by joining us on booth #40 for a drinks reception on Wednesday, 5 March at 5pm
Expert Presentation
- Learn from leading expert, Dr. Matthias P. Schönermark, at his session ‘Transforming HTA with Agility & AI – innovative approaches for the first generation of EU HTA’ at 12.20 on Thursday, 6 March
- Prof. Matthias P. Schönermark, M.D., Ph.D., is a trained head & neck surgeon holding a Ph.D. in molecular oncology. Dr. Schönermark spent several years at The Boston Consulting Group, supporting clients in the health care industry in Europe and overseas, before co-founding SKC, where he holds an unrivalled track record of solving complex and demanding market access challenges, especially in the orphan drug and oncology sector as one of the most experienced negotiation leaders in reimbursement and pricing for the German AMNOG procedure.
Kintiga CEO, Steve Glass, commented, “We look forward to not only unveiling our new brand and visual identity under the new name, but more importantly, to be able to showcase our deep expertise at both the local and European level. As Kintiga we offer our clients unparallelled support throughout the complex journey to achieve successful patient access across Europe, with our tailored approach, global perspective, and local expertise.”
About Kintiga
Kintiga is Europe’s largest independent specialist pharmaceutical and biotechnology management consultancy. Its unique capabilities enable companies to maximise the value of their product portfolios, while providing patients with life-changing health solutions, by facilitating access to medicines across Europe’s complex medical, regulatory and payer environment. Kintiga provides a unique combination of specialist consultancy products and services across the development path to commercialisation, along with an online membership platform providing uninterrupted access to experts as well as an extensive and unique database, set of tools and invaluable content, to a wide range of pharmaceutical and biotech companies across Europe. Kintiga is headquartered in the United Kingdom, with additional sites across Europe, providing its range of products and services to customers across the globe, and backed by Kester Capital.
In 2024, Kintiga, formerly the MAP Group, acquired the Belgium based consultancy, AxTalis, which broadened the Group’s capabilities, including regulatory strategy and compliance and medical affairs, in addition to strong market access capabilities in the Benelux region that complement well established existing offerings. Also in 2024, the MAP Group acquired SKC Beratungsgesellschaft mbH, a strategic consultancy based in Hannover, Germany, the leading German market access and pricing and reimbursement consultancy, supporting pharma, biotech, MedTech, and digital health companies with complex strategic issues. Kintiga has established operations across the UK, Ireland, Benelux, and Germany, with extensive experience across more than 350 clients and over 540 HTA submissions.
For more information about Kintiga, visit www.kintiga.com
Media Inquiries:
Please contact Marianne Lambertson, Chief Commercial Officer
mlambertson@kintiga.com
